Published in J Clin Invest on August 01, 1978
Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med (1981) 5.76
Serum transfer of collagen-induced arthritis in mice. J Exp Med (1983) 3.74
Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med (1982) 3.06
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med (1985) 2.92
Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J Clin Invest (1982) 2.29
Collagen-induced arthritis in the rat: modification of immune and arthritic responses by free collagen and immune anti-collagen antiserum. Immunology (1981) 1.92
Role of T lymphocytes in collagen II induced arthritis in rats. Clin Exp Immunol (1983) 1.58
Collagen-induced arthritis in mice. Localization of an arthritogenic determinant to a fragment of the type II collagen molecule. J Exp Med (1985) 1.52
Autoimmunity to collagen in adjuvant arthritis of rats. J Clin Invest (1980) 1.44
Clonal heterogeneity of synovial fluid T lymphocytes from patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.25
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol (2010) 1.16
Suppression of collagen type II-induced arthritis by transfer of lymphoid cells from rats immunized with collagen. Clin Exp Immunol (1985) 1.15
Development of an experimental animal model for reactive arthritis induced by Yersinia enterocolitica infection. Infect Immun (1987) 1.12
Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol (2009) 1.09
CD4+ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficient mice. Clin Exp Immunol (1994) 1.09
The anti-arthritic and immunosuppressive effects of cyclosporine on arthritis induced in the rat by type II collagen. Clin Exp Immunol (1984) 1.07
Synergy between adjuvant arthritis and collagen-induced arthritis in rats. J Exp Med (1985) 1.05
Pathogenetic difference between collagen arthritis and adjuvant arthritis. J Exp Med (1984) 1.02
Adoptive transfer of suppression of arthritis in the mouse model of collagen-induced arthritis. Evidence for a type II collagen-specific suppressor T cell. J Clin Invest (1985) 1.00
MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis. J Immunol (2008) 1.00
Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats. J Exp Med (1992) 1.00
Effects of various anti-inflammatory drugs on type II collagen-induced arthritis in rats. Clin Exp Immunol (1982) 1.00
Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. Br J Pharmacol (2000) 0.91
Cartilage specific collagen activates macrophages and the alternative pathway of complement: evidence for an immunopathogenic concept of rheumatoid arthritis. Ann Rheum Dis (1982) 0.91
Successful transfer of collagen-induced arthritis to severe combined immunodeficient (SCID) mice. Clin Exp Immunol (1992) 0.91
The role of neutrophils in type II collagen-induced arthritis in rats. Am J Pathol (1984) 0.89
An arthritogenic lymphokine in the rat. J Exp Med (1985) 0.88
Activation pathways of synovial T lymphocytes. Expression and function of the UM4D4/CDw60 antigen. J Clin Invest (1990) 0.88
Collagen-induced arthritis in T cell receptor V beta congenic B10.Q mice. J Exp Med (1994) 0.86
Restricted expression of anti-type II collagen antibody isotypes in mice suppressed for collagen-induced arthritis. Ann Rheum Dis (1986) 0.85
Cell-mediated transfer of collagen-induced arthritis in mice and its application to the analysis of the inhibitory effects of interferon-gamma and cyclophosphamide. Clin Exp Immunol (1993) 0.85
Carrageenan-induced arthritis in the rat. Inflammation (2000) 0.84
Adjuvant-induced arthritis in rats. Evidence that autoimmunity to homologous collagens types I, II, IX and XI is not involved in the pathogenesis of arthritis. Clin Exp Immunol (1990) 0.84
Anti-Hsp65 antibodies recognize M proteins of group A streptococci. Infect Immun (1996) 0.82
The immune response of guinea-pigs to type II collagen: poor cross-reactivity with homologous type II collagen accounts for resistance to collagen-induced arthritis. Immunology (1988) 0.81
The role of lipopolysaccharide injected systemically in the reactivation of collagen-induced arthritis in mice. Br J Pharmacol (2000) 0.81
Contribution of the spleen, lymph nodes and bone marrow to the antibody response in collagen-induced arthritis in the rat. Clin Exp Immunol (1991) 0.80
Native type II collagen-induced arthritis in the rat. III. Relationship between the cellular immune response to native type II collagen and arthritis. Ann Rheum Dis (1983) 0.79
Heart-specific autoantibodies can be eluted from the hearts of Coxsackievirus B3-infected mice. Clin Exp Immunol (1991) 0.79
Immunotherapy of experimental arthritis. Analysis of the articular cartilage of mice suppressed for collagen-induced arthritis by a T-cell hybridoma. Am J Pathol (1987) 0.78
Cellular immunity to cartilage link protein in patients with inflammatory arthritis and non-arthritic controls. Ann Rheum Dis (1995) 0.78
Rheumatoid arthritis: identifying and characterising polymorphisms using rat models. Dis Model Mech (2016) 0.77
Humoral immunity to link protein in patients with inflammatory joint disease, osteoarthritis, and in non-arthritic controls. Ann Rheum Dis (1988) 0.77
Studies on the effect of fenbufen and sulindac on type II collagen-induced arthritis in rats. Agents Actions (1982) 0.75
Stepwise inhibition of T cell recruitment at post-capillary venules by orally active desulfated heparins in inflammatory arthritis. PLoS One (2017) 0.75
Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med (1977) 10.09
A lymph node weight assay for the graft-versus-host activity of rat lymphoid cells. Transplantation (1970) 4.35
Isolation and characterization of a collagen from chick cartilage containing three identical alpha chains. Biochemistry (1971) 3.61
Quantitative studies on the mixed lymphocyte interaction in rats. I. Conditions and parameters of response. J Exp Med (1967) 3.20
Quantitative studies on the induction of tolerance of skin homografts and on runt disease in neonatal rats. J Natl Cancer Inst (1962) 3.14
Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.84
The production of specific antibodies to native collagens with the chain compositions, (alpha1(I))3, (alpha1(II))3, and (alpha1(I))2alpha 2. J Immunol (1974) 2.02
Pathogenesis of experimental allergic orchitis. II. The role of antibody. J Immunol (1971) 1.52
Synthesis of two collagen types by embryonic chick corneal epithelium in vitro. Proc Natl Acad Sci U S A (1977) 1.38
Synthesis of type II collagen in vitro by embryonic chick neural retina tissue. Proc Natl Acad Sci U S A (1976) 1.30
Pathogenesis of experimental allergic orchitis. III. T lymphocyte requirement in local adoptive transfer by peritoneal exudate cells. J Immunol (1977) 1.27
Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 12.29
Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med (1977) 10.09
Alterations of macrophage functions by mediators from lymphocytes. J Exp Med (1971) 7.95
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med (1995) 5.18
Genetic variation of Drosophila melanogaster natural populations. Trends Genet (1988) 4.62
Suppression of delayed hypersensitivity in vitro by inhibition of protein synthesis. J Exp Med (1965) 4.62
The enhancement of macrophage bacteriostasis by products of activated lymphocytes. J Exp Med (1973) 4.51
A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni. J Immunol (1979) 4.17
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07
Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med (1973) 3.98
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
An in vitro assay for cellular hypersensitivity in man. J Immunol (1970) 3.73
Cellular hypersensitivity and immunity. Inhibition of macrophage migration and the lymphocyte mediators. Prog Allergy (1972) 3.47
Macrophage migration. Fed Proc (1990) 3.39
Studies on mediator production by highly purified human T and B lymphocytes. J Exp Med (1974) 3.38
Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med (1985) 3.37
Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med (1999) 3.23
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
Studies on migration inhibitory factor (MIF): recovery of MIF activity after purification by gel filtration and disc electrophoresis. Cell Immunol (1970) 2.86
Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest (1978) 2.84
Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein. J Immunol (1979) 2.81
Cellular sensitivity to collagen in rheumatoid arthritis. N Engl J Med (1978) 2.50
Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum (1988) 2.41
Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum (1982) 2.35
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A (1989) 2.24
Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol (2001) 2.20
The compartmentalization of antigen-reactive lymphocytes in desensitized guinea pigs. J Exp Med (1971) 2.18
Metabolic and functonal studies on activated mouse macrophages. J Exp Med (1973) 2.17
Antibody-dependent eosinophil-mediated damage to 51Cr-labeled schistosomula of Schistosoma mansoni: damage by purieid eosinophils. J Exp Med (1977) 2.06
Association between bovine collagen dermal implants and a dermatomyositis or a polymyositis-like syndrome. Ann Intern Med (1993) 2.04
Macrophage activation by lymphocyte mediators. Fed Proc (1975) 1.99
Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg (1998) 1.99
Host-plant specialization in the Drosophila melanogaster species complex: a physiological, behavioral, and genetical analysis. Proc Natl Acad Sci U S A (1991) 1.98
Similarities and differences in latitudinal adaptation of two Drosophila sibling species. Nature (1975) 1.96
Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (1998) 1.93
Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci U S A (1986) 1.93
Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis (2005) 1.91
Evolution in a cosmopolitan species: genetic latitudinal clines in Drosophila melanogaster wild populations. Experientia (1975) 1.91
Immunochemical studies on the specificity of cellular hypersensitivity. The in vitro inhibition of peritoneal exudate cell migration by cehmically defined antigens. J Exp Med (1968) 1.90
Monoclonal antibodies that distinguish between New World species of Leishmania. Nature (1981) 1.89
Characterization of migration inhibitory factor (MIF) from guinea pig lymphocytes stimulated with concanavalin A. J Immunol (1972) 1.82
Mediators produced by sensitized lymphocytes. Fed Proc (1972) 1.79
Mitochondrial DNA variability in Drosophila simulans: quasi absence of polymorphism within each of the three cytoplasmic races. Heredity (Edinb) (1988) 1.76
Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol (2001) 1.74
Activation of human blood monocytes by products of sensitized lymphocytes. J Clin Invest (1974) 1.73
Maternal-fetal relation. Absence of an immunologic blocking factor from the serum of women with chronic abortions. N Engl J Med (1976) 1.69
Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll. Exp Parasitol (1982) 1.66
Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies. Am J Trop Med Hyg (1987) 1.65
Prevention of MIF activity by agents known to increase cellular cyclic AMP. J Immunol (1973) 1.64
Transfer of cellular hypersensitivity in chronic mucocutaneous candidiasis monitored in vivo and in vitro. Cell Immunol (1970) 1.64
In vivo and in vitro characterization of murine T-cell clones reactive to Mycobacterium tuberculosis. Infect Immun (1987) 1.63
Characterization of human migration inhibitory factor (MIF) from antigen-stimulated lymphocytes. Cell Immunol (1972) 1.63
Synovial fluid tests. What should be ordered? JAMA (1990) 1.55
Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A (1981) 1.54
Lymphocyte mediators and cellular hypersensitivity. N Engl J Med (1973) 1.53
Schistosoma mansoni. Anti-egg monoclonal antibodies protect against cercarial challenge in vivo. J Exp Med (1984) 1.51
Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia. N Engl J Med (1980) 1.50
Genetics of morphological differences and hybrid sterility between Drosophila sechellia and its relatives. Genet Res (1991) 1.49
Morphologic demonstration of two stages in the development of type II collagen-induced arthritis. Lab Invest (1982) 1.47
Enzymatic and quantitative variation in European and African populations of Drosophila simulans. Heredity (Edinb) (1985) 1.47
The Guillain-Barré syndrome and multiple sclerosis. In vitro cellular responses to nervous-tissue antigens. N Engl J Med (1971) 1.47
Biological expressions of lymphocyte activation. V. Characterization of a soluble immune response suppressor (SIRS) produced by concanavalin A-activated spleen cells. J Immunol (1976) 1.47
Autoimmunity to collagen in adjuvant arthritis of rats. J Clin Invest (1980) 1.44
Low allozyme and mtDNA variability in the island endemic species Drosophila sechellia (D. melanogaster complex). Experientia (1990) 1.42
In vitro studies of the suppression of delayed hypersensitivity by the induction of partial tolerance. J Exp Med (1970) 1.41
Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med (1987) 1.41
Stress-induced enhancement of skin immune function: A role for gamma interferon. Proc Natl Acad Sci U S A (2000) 1.39
IgE antibody and resistance to infection. I. Selective suppression of the IgE antibody response in rats diminishes the resistance and the eosinophil response to Trichinella spiralis infection. J Exp Med (1981) 1.36
Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun (2001) 1.36
In vitro lymphocyte response of patients with immunologic deficiency diseases. N Engl J Med (1970) 1.34
Interactions between human eosinophils and schistosomula of Schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence. J Exp Med (1979) 1.34
Retracted Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani. J Immunol (1991) 1.33
In vitro evidence for cellular hypersensitivity to glomerular-basement-membrane antigens in human glomerulonephritis. N Engl J Med (1970) 1.33
Retracted Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages. J Immunol (1993) 1.31
Further studies on migration inhibitory factor (MIF): evidence for its glycoprotein nature. J Immunol (1971) 1.30
Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells. J Immunol (1975) 1.27
Monoclonal antibodies that distinguish subspecies of Leishmania braziliensis. J Immunol (1982) 1.27
Biosynthetic defect in monocytes from human beings with genetic deficiency of the second component of complement. N Engl J Med (1975) 1.27
A microsatellite-based multilocus phylogeny of the Drosophila melanogaster species complex. Curr Biol (1998) 1.26
Antigen-specific suppression of type II collagen-induced arthritis by collagen-coupled spleen cells. J Immunol (1982) 1.25
Pathogenesis of rheumatoid arthritis. Lancet (1993) 1.25
Enhancement of human blood eosinophil cytotoxicity by semi-purified eosinophil colony-stimulating factor(s). J Exp Med (1982) 1.25
Comparative analysis of morphological traits among Drosophila melanogaster and D. simulans: genetic variability, clines and phenotypic plasticity. Genetica (2004) 1.23
In vitro demonstration of cellular sensitivity in allergic encephalomyelitis. J Exp Med (1965) 1.22
Competence of the human host as a reservoir for Leishmania chagasi. J Infect Dis (2000) 1.21
Short-range genetic structure of Drosophila melanogaster populations in an Afrotropical urban area and its significance. Proc Natl Acad Sci U S A (1989) 1.21
Leukocyte inhibitory factor (LIF): production by purified human T and B lymphocytes. J Immunol (1975) 1.19
Biological role of alcohol dehydrogenase in the tolerance of Drosophila melanogaster to aliphatic alochols: utilization of an ADH-null mutant. Biochem Genet (1976) 1.19
Multilevel modelling of the incidence of visceral leishmaniasis in Teresina, Brazil. Epidemiol Infect (2006) 1.19
In vitro killing of S. mansoni schistosomula by lymphokine-activated mouse macrophages. J Immunol (1981) 1.18
IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol (2000) 1.17
Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis. N Engl J Med (1981) 1.17